Professor Wei Lijuan mainly specializes in early diagnosis of breast cancer, risk assessment, genetic counseling of familial hereditary breast cancer, cancer prevention, and personalized screening. Major publications: [1]Wei L, Zhu S, Li M, Li F, Wei F, Liu J, Ren X. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer. Front Immunol. 2018 Apr 17;9:724.doi: 10.3389/fimmu.2018.00724. [2]Wei L, Wu N, Wei F, Li F, Zhang Y, Liu J, Ren X. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer. Int Immunopharmacol. 2020 Jul;84:106506. doi: 10.1016/j.intimp.2020.106506. [3]Wu N, Wei L, Li L, Li F, Yu J, Liu J. Perspectives on the role of breast cancer susceptibility gene in breast cancer. Int J Clin Oncol. 2022 Mar;27(3):495-511. doi: 10.1007/s10147-021-02098-1. [4]Mu K, Wu ZZ, Yu JP, Guo W, Wu N, Wei LJ, Zhang H, Zhao J, Liu JT. Meta-analysis of the association between three microRNA polymorphisms and breast cancer susceptibility. Oncotarget. 2017 Jun 16;8(40):68809-68824. doi: 10.18632/oncotarget.18516.